LCTX

LCTX EBITDA Margin

-280.10%TTM

Period ending:

LCTX FY EBITDA Margin%
LCTX FY EBITDA Margin1013.74%-10685.70%
1992-06-302025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

LCTX ebitda margin history

EBITDA as a percentage of revenue. The available annual fiscal periods series contains 34 observations from Jun 30, 1992 to Dec 31, 2025.

Lineage Cell Therapeutics, Inc. Common Stock EBITDA Margin — Annual fiscal periods
Period endingEBITDA Margin
-466.8041%
-189.2094%
-252.5433%
-170.6114%
-1,088.2187%
-3,157.5679%
-2,427.3342%
-2,663.9831%
-2,084.8214%
-2,407.1936%
-2,347.0797%
-2,171.7842%
-1,208.4556%
-1,309.4483%
-374.8054%
-242.4628%
-181.0582%
-186.0874%
-118.4661%
-150.7609%
-220.2056%
-268.8965%
-158.0175%
-394.7814%
-2,105.7472%
-9,553.4977%
-549.4141%
-800%
-3,650%
-3,200%
-2,000%
-2,500%
-1,600%
-1,300%

Compare ebitda margin

All LCTX financial metrics · LCTX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.